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The prevention and/or rescue of babies at risk of bronchopulmonary dysplasia (BPD) has focused 
upon the use of maternal antenatal steroids (1), surfactant (2), diuretics (3), and postnatal use of 
steroids along with various ventilator support strategies.
With regard to the evidence informing the use of steroids, there is no lack of data. Systemic 
corticosteroid administration (predominantly dexamethasone) through the immediate postnatal 
(4), moderate early (5) and late (6) periods, result in improved pulmonary outcomes (4–6) at a cost 
of short-term adverse effects (4). The use of corticosteroid treatment to treat or prevent development 
of established BPD remains controversial, however, largely due to concerns of neurodevelopmental 
sequelae. These are largely driven by one study (7), but as a whole, the inclusion of very varied steroid 
administration strategies in the same analyses make interpretation difficult.
Recently, a series of multicentre, randomized, adequately powered, controlled trials (summarized 
in Table 1) have examined the use of alternative corticosteroids [hydrocortisone or betamethasone 
(8)] at lower systemic doses (9) or lung administration either through nebulization (10) or direct 
instillation (11) to limit systemic exposure.
The PREMILOC study (9) of low-dose hydrocortisone (1 mg/kg for 7 days with a 3-day wean; 
8.5 mg/kg cumulative dose) recruited 523 extremely premature infants within the first day of life. 
The primary outcome was survival without BPD at 36 weeks of post menstrual age. The trial was 
stopped early due to “financial and technical support limitations,” and the planned analysis was 
adjusted as a result. 153 (60%) out of 255 infants assigned to receive hydrocortisone and 136 (51%) 
out of 266 infants assigned to placebo, survived without BPD. The effect size, adjusted for gestation, 
and the effect of repeated analyses in the statistical method was statistically significant – OR 1·48 
(95% CI 1·02–2·16; p = 0·04). The number needed to treat (NNT) to achieve one BPD-free survival 
was 12 (95% CI 6–200). There was a significantly increased risk of late onset sepsis in those born 
at 24–25 weeks gestation given hydrocortisone (33/83; 40%) compared with placebo (21/90; 23%). 
Unfortunately, long-term neurodevelopmental outcome is not yet reported; however, MRI findings 
as a surrogate were available in 80% of the survivors with 30% of infants in each group demonstrating 
detectable lesions at term-corrected gestations.
The NEUROSIS trial (10) of inhaled budesonide (400 μg twice daily via a spacer for 2 weeks, then 
once daily until supplemental oxygen was not required or infant reached 32 weeks PMA) or placebo 
recruited 863 infants who needed respiratory pressure support in 40 centers in 9 European countries. 
Primary outcome was identical to the PREMILOC study (except rate of death or BPD at 36 weeks 
PMA). In a per-protocol analysis of 437 infants randomized to receive budesonide, 175 (40%) died 
or developed BPD compared with 194 out of 419 (46.3%) infants in the placebo group (effect size 
OR 0.71; 95% CI 0.53–0.97; p = 0.03). Those receiving budesonide appeared to come out of oxygen 
earlier and fewer babies required re-intubation. Unfortunately, neurodevelopmental outcomes 
are as yet unreported. In contrast, these were reported in a multicentre trial from Japan, where 
TABLE 1 | Trials of alternative route or dose of corticosteroids in BpD.
Study patients intervention Control Outcome
Bassler  
et al. (10)
863 extremely preterm 
infants (<28 weeks 
gestation) requiring any 
positive pressure support in 
the first 12 h of life in centers 
in Europe and the US
441 infants were assigned to receive 
400 μg budesonide 12 hourly for 
14 days and 200 μg 12 hourly until no 
longer needing supplemental oxygen 
or reaching 32 weeks corrected 
gestation (whichever sooner)
422 infants were assigned 
to receive placebo 12 hourly 
until no longer needing 
supplemental oxygen or 
reaching 32 weeks corrected 
gestation (whichever sooner)
175 out of 437 (40%) infants who received 
budesonide died or had BPD compared to 
194 out of 419 (46.3%) in the control group; 
OR 0.71, 95% CI 0.53–0.97, p = 0.03
Baud  
et al. (9)
523 extremely preterm 
infants inborn (born in a 
maternity ward at the same 
site as the NICU) at less 
than 28 weeks of gestation 
at 21 French centers
255 infants received 1 mg/kg 
hydrocortisone per day divided 
into two doses per day for 7 days, 
followed by one dose of 0·5 mg/kg 
per day for 3 days
267 infants received placebo 
(5% dextrose)
A greater proportion of infants who received 
hydrocortisone, 153 out of 255 (60%) 
survived without BPD, compared with 136 
(51%) out of 266 infants assigned to placebo. 
OR (adjusted for gestational age group and 
interim analyses) 1·48, 95% CI 1·02–2·16, 
p = 0·04. NNT 12, 95% CI 6–200
Nakamura  
et al. (12)
211 infants with birthweight 
<1000 g who needed 
intubation for respiratory 
support in Japan
107 infants received two doses of 
50 μg of Fluticasone or placebo were 
administered every 24 h via the spacer 
device starting within 24 h of birth 
and continuing until 6 weeks of age or 
extubation
104 infants received  
placebo
No difference between groups in incidences 
of death or oxygen dependence at discharge 
(RR 0.94, 95% CI 0.72–1.23). The 24–26 GA 
subgroup analyses demonstrated that death 
and oxygen dependence at discharge were 
significantly lower in the Fluticasone group 
(RR 0.43, 95% CI 0.20–0.92)
Yeh et al.  
(11)
265 very-low-birth-weight 
infants (<1500 g) in the US 
& Taiwan with severe RDS 
who required mechanical 
ventilation and FiO2 >50% 
within 4 h of birth
131 infants received surfactant 
(100 mg/kg) and budesonide 
(0.25 mg/kg) 8 hourly until FiO2 <30%
131 infants received 
surfactant (100 mg/kg). 
Only 8 hourly until FiO2 
<30%
Infants in the budesonide group had a lower 
incidence of BPD or death [55 out of 131 
(42.0%) vs. 89 out of 134 (66%) respectively; 
RR, 0.58, 95% CI 0.44–0.77, p = 0.001; NNT 
4.1 95% CI 2.8–7.8]
2
Hurley and Bhatt Corticosteroids and Bronchopulmonary Dysplasia
Frontiers in Pediatrics | www.frontiersin.org August 2016 | Volume 4 | Article 85
infants were randomized to receive inhaled fluticasone (n = 107) 
or placebo (n =  104). No significant differences were detected 
between the groups with respect to either the frequency of death, 
oxygen dependence at discharge, or neurodevelopmental impair-
ment at 18 months and 3 years PMA. In subgroup analyses, the 
frequencies of death and oxygen dependence at discharge were 
significantly decreased in the fluticasone group for infants born 
at 24–26 weeks and for infants with chorioamnionitis, regardless 
of the gestational age at birth (12).
In the study by Yeh et  al. (11), 265 very-low-birth-weight 
(<1500  g) infants with severe respiratory distress syndrome 
requiring invasive ventilation were randomised to receive either 
intratracheal surfactant alone or in a combination mixed with 
budesonide (0.25  mg or 1  ml/kg). Doses were repeated every 
8 h until infants, required less than 30% oxygen, were extubated 
or had received a maximum of six doses. The primary outcome 
measure was again identical to the two other studies. Infants in 
the combined surfactant-budesonide group had a lower inci-
dence of BPD or death (55 out of 131, 42%) compared with those 
in the surfactant-only group (89 out of 134, 66%) (RR 0.58; 95% 
CI 0.44–0.77; p <  0.001). The NNT was 4.1 (95% CI 2.8–7.8). 
With 85% of the cohort under follow-up at 30 months of age, the 
proportions of infants described as having “neurodevelopmental 
impairment” were 26 out of 85 (30.6%) in the intervention group 
compared with 34 out of 87 (39.1%) in the control group, with 
follow-up ongoing.
The four recent studies report the use of local/lower dose cor-
ticosteroid to prevent BPD/death and find a significant beneficial 
effect, at least in selected groups of babies. This is unsurprising as 
efficacy has really not been in doubt, although, it is encouraging 
that a reduced dose exerts a similar effect. It is disappointing that, 
as yet, the factor limiting adoption, neurodevelopmental impair-
ment, has not been reported in three of these studies, and these 
studies are unlikely to change practice until it is.
While these data add to evidence for preventing BPD, there 
remains a large void in the evidence base informing the treatment 
of those with established severe BPD. Indeed, the current stud-
ies appear to show no promise for this small group of infants as 
the proportion of infants with very severe BPD was no different 
between treatment and control groups in the PREMILOC study 
(9). Management for these infants is likely to vary to an even 
greater degree than the approach taken across units or countries 
(13) with the use of steroids for all premature infants (14). One 
approach extrapolates the strategy used for childhood interstitial 
lung disease (15) but restricts it to those considered to have 
life-threateningly very severe BPD with an objective measure of 
severity.
While the studies that have been completed need follow-up 
in order to report neurodevelopmental outcome, the pendulum 
does appear to have come back toward the center in terms of 
steroid use in preventing BPD. In the case of established, very 
severe BPD, it is not just a case of “more studies are needed,” one 
study would be a start.
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